Unknown

Dataset Information

0

Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.


ABSTRACT: Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving in order to aid clinical decisions remains difficult. This is because ctDNA is a mix of fragmented alleles, and the contribution of different cancer deposits to ctDNA is largely unknown. Profiling ctDNA almost invariably requires prior knowledge of what genomic alterations to track. Here, we leverage on a rapid autopsy programme to demonstrate that unbiased genomic characterisation of several metastatic sites and concomitant ctDNA profiling at whole-genome resolution reveals the extent to which ctDNA is representative of widespread disease. We also present a methylation profiling method that allows tracking evolutionary changes in ctDNA at single-molecule resolution without prior knowledge. These results have critical implications for the use of liquid biopsies to monitor cancer evolution in humans and guide treatment.

SUBMITTER: Cresswell GD 

PROVIDER: S-EPMC7101390 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.

Cresswell George D GD   Nichol Daniel D   Spiteri Inmaculada I   Tari Haider H   Zapata Luis L   Heide Timon T   Maley Carlo C CC   Magnani Luca L   Schiavon Gaia G   Ashworth Alan A   Barry Peter P   Sottoriva Andrea A  

Nature communications 20200327 1


Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving in order to aid clinical decisions remains difficult. This is because ctDNA is a mix of fragmented alleles, and the contribution of different cancer deposits to ctDNA is largely unknown. Profiling ctDNA almost invariably requires prior knowledge of what genomic alterations to  ...[more]

Similar Datasets

| EGAS00001004014 | EGA
| S-EPMC7614605 | biostudies-literature
| S-EPMC6785899 | biostudies-other
| S-EPMC9356206 | biostudies-literature
| S-EPMC3288636 | biostudies-literature
| S-EPMC4662490 | biostudies-literature
2011-12-13 | E-GEOD-34356 | biostudies-arrayexpress
2011-12-13 | GSE34356 | GEO
| S-EPMC6856766 | biostudies-literature
| S-EPMC4829845 | biostudies-literature